Literature DB >> 30737898

Novel insights into the systemic treatment of lung cancer malignant pleural effusion.

Claire Tissot1, Pierre Gay1, Clément Brun1, Marios E Froudarakis1.   

Abstract

Lung cancer is the most common fatal malignancy worldwide. Approximately 75% of non-small-cell lung cancer (NSCLC) patients are diagnosed at an advanced or a metastatic stage. Since 2007, NSCLC patients with malignant pleural effusion (MPE) are staged as M1 disease. During the last decades, chemotherapeutic agents failed to offer a significant improvement of survival in patients with metastatic disease. The current review aims to summarize the actual situation of the recently developed therapies in patients with lung cancer and MPE.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  immunotherapy; lung cancer; malignant pleural effusion; pleural disease; targeted therapy; treatment

Mesh：

Substances：

Year:  2019        PMID： 30737898     DOI： 10.1111/crj.13005

Source DB:  PubMed          Journal:  Clin Respir J        ISSN： 1752-6981            Impact factor:   2.570


  4 in total

1.  Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.

Authors:  Zhangqiang Xiang; Xiangyu Deng; Wenfeng He; Qian Yang; Laichao Ni; Marzieh Dehghan Shasaltaneh; Mazaher Maghsoudloo; Gang Yang; Jingbo Wu; Saber Imani; Qinglian Wen
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

2.  Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.

Authors:  Ying Liu; Ying Cheng; Qiming Wang; Kai Li; Jianhua Shi; Lin Wu; Baohui Han; Gongyan Chen; Jianxing He; Jie Wang; Haifeng Qin; Xiaoling Li
Journal:  Thorac Cancer       Date:  2021-10-01       Impact factor: 3.500

3.  Prognostic role of immune microenvironment in pleural metastases from breast and lung adenocarcinomas.

Authors:  Georgia Karpathiou; Jonas Benli; Anne Laure Désage; Mathilde Jacob; Olivier Tiffet; Michel Peoc'h; Marios E Froudarakis
Journal:  Ann Transl Med       Date:  2022-04

4.  Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review.

Authors:  Shunkai Zhou; Rongzhi Huang; Yunpeng Cao
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.